Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia.
about
Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis.Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis.Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.Could high-concentration rifampicin kill rifampicin-resistant M. tuberculosis? Rifampicin MIC test in rifampicin-resistant isolates from patients with osteoarticular tuberculosis.Mycobacterium ulcerans disease: experience with primary oral medical therapy in an Australian cohort.Therapeutic drug monitoring in the treatment of active tuberculosisExposure to total and protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients.Low Serum Concentrations of Moxifloxacin, Prothionamide, and Cycloserine on Sputum Conversion in Multi-Drug Resistant TB.Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears.Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIVReduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines.Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorptionA simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children.Relative bioavailability of rifampicin in four Chinese fixed-dose combinations compared with rifampicin in free combinations.Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes.Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs.Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes.Factors Influencing Tuberculosis Treatment Outcome in Adult Patients Treated with Thrice-Weekly Regimens in India.Evaluation of high- versus standard-dose rifampin in Indonesian patients with pulmonary tuberculosis.Delayed Sputum Conversion in TB-HIV Co-Infected Patients with Low Isoniazid and Rifampicin Concentrations.The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs
P2860
Q33282527-9FAC1FF5-7F9F-4C12-A298-88C91A3F496EQ33433684-F8094CBE-4D61-44D3-9308-CF87A52BBF11Q33797850-0F78ECC7-2802-4D85-9192-F7BC52EE2BDDQ33843657-A7E4534C-CCB1-40BC-A0C3-1B6020016B29Q34150929-8668A3A0-A5D2-4B0B-B490-25AAD6D5384FQ34510679-B4ACF326-D59E-4FB2-9C56-9CCC4F1088A3Q34728759-393F9DDF-4F84-4ED4-81A6-E1562C3313E5Q34855365-61B2282F-B82C-4F60-B6AD-C74A4D102C5DQ35487794-417E2BB7-7938-4804-84F2-CE96C11AB03DQ35584822-BA5B21AD-310C-4F56-8A12-47B18A7E18E2Q35778303-6AE841EB-E1D9-4BD7-87EF-4B9898E172DEQ35912691-D1E0C82C-C9DE-4176-AC54-97F7BA302FC9Q35941434-DA16E566-26C6-4DDF-A08A-B1CE19323AE9Q36018761-C82D29EA-5444-4C78-B2C0-1CCD961F36E4Q36702972-5950D12C-9BE5-4140-A820-C235A9B87295Q36706812-0A01E898-C0A8-4C50-BF26-5FCC4094D3C7Q36811624-E15C928C-A554-4666-B87C-406A1F1BC039Q37162418-3E09DA66-4D22-4F52-8A7F-0737435EA5BDQ37247736-A5139B8B-C2E6-4CF5-A104-FE5E6AC6B681Q42281128-8F83365B-790B-4879-BB93-82BD00C1283CQ42358805-8F9B1146-E57E-4140-A3AA-024D660155ADQ43203258-D63C8476-2E54-4707-A01D-48F7BF0E096AQ52669182-3E27181E-FA75-4245-AF05-F4AACF1E83A5Q56912878-A441A4C0-FB5B-4B61-88B9-C02149369C80
P2860
Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia.
@ast
Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia.
@en
type
label
Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia.
@ast
Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia.
@en
prefLabel
Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia.
@ast
Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia.
@en
P2093
P356
P1476
Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia
@en
P2093
B Alisjahbana
H Danusantoso
J W M van der Meer
R H H Nelwan
R van Crevel
W C M de Lange
P304
P356
10.5588/09640569513002
P577
2002-06-01T00:00:00Z